Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1963 2
1964 4
1965 2
1967 8
1968 7
1969 7
1970 1
1971 2
1972 1
1973 1
1974 3
1975 1
1976 1
1978 1
1983 1
1987 1
1989 1
1993 2
1998 2
1999 2
2000 1
2001 1
2002 2
2003 2
2004 1
2005 2
2006 1
2007 1
2008 3
2009 3
2010 1
2011 5
2012 3
2013 1
2014 3
2015 1
2016 7
2017 8
2018 8
2019 5
2020 9
2021 17
2022 12
2023 9
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Results by year

Filters applied: . Clear all
Page 1
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells.
Codarri Deak L, Nicolini V, Hashimoto M, Karagianni M, Schwalie PC, Lauener L, Varypataki EM, Richard M, Bommer E, Sam J, Joller S, Perro M, Cremasco F, Kunz L, Yanguez E, Hüsser T, Schlenker R, Mariani M, Tosevski V, Herter S, Bacac M, Waldhauer I, Colombetti S, Gueripel X, Wullschleger S, Tichet M, Hanahan D, Kissick HT, Leclair S, Freimoser-Grundschober A, Seeber S, Teichgräber V, Ahmed R, Klein C, Umaña P. Codarri Deak L, et al. Among authors: sam j. Nature. 2022 Oct;610(7930):161-172. doi: 10.1038/s41586-022-05192-0. Epub 2022 Sep 28. Nature. 2022. PMID: 36171284 Free PMC article.
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.
Claus C, Ferrara C, Xu W, Sam J, Lang S, Uhlenbrock F, Albrecht R, Herter S, Schlenker R, Hüsser T, Diggelmann S, Challier J, Mössner E, Hosse RJ, Hofer T, Brünker P, Joseph C, Benz J, Ringler P, Stahlberg H, Lauer M, Perro M, Chen S, Küttel C, Bhavani Mohan PL, Nicolini V, Birk MC, Ongaro A, Prince C, Gianotti R, Dugan G, Whitlow CT, Solingapuram Sai KK, Caudell DL, Burgos-Rodriguez AG, Cline JM, Hettich M, Ceppi M, Giusti AM, Crameri F, Driessen W, Morcos PN, Freimoser-Grundschober A, Levitsky V, Amann M, Grau-Richards S, von Hirschheydt T, Tournaviti S, Mølhøj M, Fauti T, Heinzelmann-Schwarz V, Teichgräber V, Colombetti S, Bacac M, Zippelius A, Klein C, Umaña P. Claus C, et al. Among authors: sam j. Sci Transl Med. 2019 Jun 12;11(496):eaav5989. doi: 10.1126/scitranslmed.aav5989. Sci Transl Med. 2019. PMID: 31189721 Free PMC article.
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.
Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, Bianchi R, Richard M, Schoenle A, Nicolini V, Diggelmann S, Limani F, Schlenker R, Hüsser T, Richter W, Bray-French K, Hinton H, Giusti AM, Freimoser-Grundschober A, Lariviere L, Neumann C, Klein C, Umaña P. Bacac M, et al. Among authors: sam j. Clin Cancer Res. 2018 Oct 1;24(19):4785-4797. doi: 10.1158/1078-0432.CCR-18-0455. Epub 2018 May 1. Clin Cancer Res. 2018. PMID: 29716920
Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.
Augsberger C, Hänel G, Xu W, Pulko V, Hanisch LJ, Augustin A, Challier J, Hunt K, Vick B, Rovatti PE, Krupka C, Rothe M, Schönle A, Sam J, Lezan E, Ducret A, Ortiz-Franyuti D, Walz AC, Benz J, Bujotzek A, Lichtenegger FS, Gassner C, Carpy A, Lyamichev V, Patel J, Konstandin N, Tunger A, Schmitz M, von Bergwelt-Baildon M, Spiekermann K, Vago L, Jeremias I, Marrer-Berger E, Umaña P, Klein C, Subklewe M. Augsberger C, et al. Among authors: sam j. Blood. 2021 Dec 23;138(25):2655-2669. doi: 10.1182/blood.2020010477. Blood. 2021. PMID: 34280257 Free PMC article.
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity.
Solomon I, Amann M, Goubier A, Arce Vargas F, Zervas D, Qing C, Henry JY, Ghorani E, Akarca AU, Marafioti T, Śledzińska A, Werner Sunderland M, Franz Demane D, Clancy JR, Georgiou A, Salimu J, Merchiers P, Brown MA, Flury R, Eckmann J, Murgia C, Sam J, Jacobsen B, Marrer-Berger E, Boetsch C, Belli S, Leibrock L, Benz J, Koll H, Sutmuller R, Peggs KS, Quezada SA. Solomon I, et al. Among authors: sam j. Nat Cancer. 2020 Dec;1(12):1153-1166. doi: 10.1038/s43018-020-00133-0. Epub 2020 Nov 9. Nat Cancer. 2020. PMID: 33644766 Free PMC article.
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy.
Waldhauer I, Gonzalez-Nicolini V, Freimoser-Grundschober A, Nayak TK, Fahrni L, Hosse RJ, Gerrits D, Geven EJW, Sam J, Lang S, Bommer E, Steinhart V, Husar E, Colombetti S, Van Puijenbroek E, Neubauer M, Cline JM, Garg PK, Dugan G, Cavallo F, Acuna G, Charo J, Teichgräber V, Evers S, Boerman OC, Bacac M, Moessner E, Umaña P, Klein C. Waldhauer I, et al. Among authors: sam j. MAbs. 2021 Jan-Dec;13(1):1913791. doi: 10.1080/19420862.2021.1913791. MAbs. 2021. PMID: 33974508 Free PMC article.
Osteogenesis Imperfecta.
Sam JE, Dharmalingam M. Sam JE, et al. Indian J Endocrinol Metab. 2017 Nov-Dec;21(6):903-908. doi: 10.4103/ijem.IJEM_220_17. Indian J Endocrinol Metab. 2017. PMID: 29285457 Free PMC article. Review.
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.
Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, Bodmer W, Lehmann S, Hofer T, Hosse RJ, Moessner E, Ast O, Bruenker P, Grau-Richards S, Schaller T, Seidl A, Gerdes C, Perro M, Nicolini V, Steinhoff N, Dudal S, Neumann S, von Hirschheydt T, Jaeger C, Saro J, Karanikas V, Klein C, Umaña P. Bacac M, et al. Among authors: sam j. Clin Cancer Res. 2016 Jul 1;22(13):3286-97. doi: 10.1158/1078-0432.CCR-15-1696. Epub 2016 Feb 9. Clin Cancer Res. 2016. PMID: 26861458
Phenylalkylamines.
Sam J. Sam J. J Pharm Sci. 1967 Oct;56(10):1344-7. doi: 10.1002/jps.2600561029. J Pharm Sci. 1967. PMID: 6059459 No abstract available.
Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies.
Leclercq-Cohen G, Steinhoff N, Albertí Servera L, Nassiri S, Danilin S, Piccione E, Yángüez E, Hüsser T, Herter S, Schmeing S, Gerber P, Schwalie P, Sam J, Briner S, Jenni S, Bianchi R, Biehl M, Cremasco F, Apostolopoulou K, Haegel H, Klein C, Umaña P, Bacac M. Leclercq-Cohen G, et al. Among authors: sam j. Clin Cancer Res. 2023 Nov 1;29(21):4449-4463. doi: 10.1158/1078-0432.CCR-22-3667. Clin Cancer Res. 2023. PMID: 37379429 Free PMC article.
154 results